Healthcare Review: Valeant, Novartis, Hospital Corp of America, Allergan, GW Pharmaceuticals Print E-mail
By Staff and Wire Reports   
Tuesday, 22 April 2014 13:32
U.S. stocks rose on Tuesday, with both the S&P 500 and Nasdaq on track for a sixth straight day of gains as a number of bellwether companies reported strong results. Netflix Inc surged 7.1 percent to $373.13 a day after results showed strong subscriber growth, a sign the trading favorite still had room to grow despite recent concerns over its valuation., Also helping lift the Internet space was Facebook Inc , which rose 2.3 percent to $62.64 after Credit Suisse upgraded the social networking company to "outperform."

David Faber reports Valeant ($VRX) will make a $45B+ hostile bid for Allergan ($AGN), of which 1/3 will be financed with cash. He expects an announcement tomorrow. After factoring a 6% gain in regular trading a 19.7% AH gain, Allergan is currently worth $50.9B..Valeant and Bill Ackman's Pershing Square Capital have each filed 13Ds (I, II) stating Pershing Square now has a 9.7% stake in Allergan. Valeant says it expects to propose a merger with a ~$15B cash component, and that it's contributing $75.9M in working capital to an entity (known as PS Fund 1) to be used by Valeant and Pershing to pursue their bid.

Novartis ($NVS) has agreed to exchange certain assets with GlaxoSmithKline ($GSK) and it is selling its animal-health division to Eli Lilly ($LLY) for around $5.4B.Novartis will buy GSK's oncology products for an initial $14.5B and up to $1.5B in development milestones. The Swiss company will also sell its vaccines business to its U.K. rival for $5.25B upfront and as much as $1.8B in milestones, as well as royalties. The latter deal doesn't include Novartis' flu business, which the company plans to sell separately.

Hospital Corp of America ($HCA) is among a number of suitors interested in acquiring Healthscope, an Australian hospital and pathology company being sold by private-equity owners Carlyle (CG) and TPG, the WSJ reports. A deal could be worth $5B.Other prospective buyers for Healthscope include China's Shanghai Fosun Pharmaceutical and Malaysia's IHH Healthcare (IHHHF).Alternatively, Healthscope could carry out an IPO.

Allergan ($AGN) has had no discussions with Valeant ($VRX) or Bill Ackman's Pershing Square about a possible takeover of the Botox maker, nor has it received an offer. Allergan's board would evaluate any offer that was made, the company said. It was responding to filings by Valeant and Peshing Square about a potential deal.

Shares of cannabinoid biopharmaceutical firm GW Pharmaceuticals ($GWPH) are up 7% after Morgan Stanley initiates coverage with an Overweight rating and $103 PT. Bank of America has a PT of $93, Piper Jaffray has $97 and Leerik Swann $79.The company's lead products are GWP42006 for epilepsy, GWP42004 for Type 2 diabetes and GWP42003 for schizophrenia.GWP42006's active ingredient is the non-psychoactive cannabinoid cannabidivarin extracted from the cannabis plant. A Phase 2 clinical trial should start later this year.

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter